A NEW drug to treat malaria, the first such therapy to get approval in 60 years, has been given the green light by the United States Food and Drug Administration.
The medicine, tafenoquine, is specifically for the recurring form of malaria, which makes 8.5 million people ill each year and can remain dormant in the liver for years before reawakening many times.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jul 18
